These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9199822)
21. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Castaman G; Tosetto A; Ruggeri M; Rodeghiero F Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192 [TBL] [Abstract][Full Text] [Related]
22. Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Gouault-Heilmann M; Leroy-Matheron C Thromb Res; 1996 May; 82(3):281-3. PubMed ID: 8732632 [No Abstract] [Full Text] [Related]
23. Activated-protein-C resistance in cancer patients. Green D; Maliekel K; Sushko E; Akhtar R; Soff GA Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127 [TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis. Gessoni G; Valverde S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946 [TBL] [Abstract][Full Text] [Related]
25. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Castoldi E; Kalafatis M; Lunghi B; Simioni P; Ioannou PA; Petio M; Girolami A; Mann KG; Bernardi F Thromb Haemost; 1998 Sep; 80(3):403-6. PubMed ID: 9759618 [TBL] [Abstract][Full Text] [Related]
26. An improved test to identify aPC-resistant factor V-Leiden. Preda L; Erba N; Figini S; Carniti GC; Rossi E Thromb Res; 1997 Jun; 86(6):461-8. PubMed ID: 9219326 [TBL] [Abstract][Full Text] [Related]
27. High sensitivity and specificity of a coagulation assay for the detection of heterozygous and homozygous factor V Leiden--based resistance to activated protein C. Riewald M; Hintz G; Ritter M; Schmidt M; Neubauer A; Riess H Blood; 1996 Dec; 88(11):4398-9. PubMed ID: 8943880 [No Abstract] [Full Text] [Related]
28. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Castaman G; Lunghi B; Missiaglia E; Bernardi F; Rodeghiero F Br J Haematol; 1997 Nov; 99(2):257-61. PubMed ID: 9375735 [TBL] [Abstract][Full Text] [Related]
29. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. Kerschen E; Hernandez I; Zogg M; Maas M; Weiler H J Thromb Haemost; 2015 Jun; 13(6):1073-80. PubMed ID: 25690763 [TBL] [Abstract][Full Text] [Related]
30. The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Leroy-Matheron C; Levent M; Pignon JM; Mendonça C; Gouault-Heilmann M Thromb Haemost; 1996 Jan; 75(1):4-10. PubMed ID: 8713771 [TBL] [Abstract][Full Text] [Related]
31. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden. Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186 [TBL] [Abstract][Full Text] [Related]
32. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke. De Lucia D; Papa ML; Ammendola F; Pezzella S; Del Giudice V; Marotta R; Renis V; Di Mauro C; Maisto G; Masi S; Nina P; Franco A; Schisano G J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665 [TBL] [Abstract][Full Text] [Related]
33. Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Kalafatis M; Lu D; Bertina RM; Long GL; Mann KG Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2181-7. PubMed ID: 7489240 [TBL] [Abstract][Full Text] [Related]
34. Effects of oral contraceptives on hemostasis and thrombosis. Rosing J; Tans G Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524 [TBL] [Abstract][Full Text] [Related]
35. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Bernardi F; Faioni EM; Castoldi E; Lunghi B; Castaman G; Sacchi E; Mannucci PM Blood; 1997 Aug; 90(4):1552-7. PubMed ID: 9269773 [TBL] [Abstract][Full Text] [Related]
36. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971 [TBL] [Abstract][Full Text] [Related]
37. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Nicolaes GA; Thomassen MC; Tans G; Rosing J; Hemker HC Blood Coagul Fibrinolysis; 1997 Jan; 8(1):28-38. PubMed ID: 9105635 [TBL] [Abstract][Full Text] [Related]
38. Diagnosis strategies in activated protein C resistance: is genotyping still necessary? Biron C; Lamarti H; Schved JF; Jeanjean P; Masmejean C; Claustres M; Aguilar-Martinez P Clin Lab Haematol; 1997 Mar; 19(1):67-71. PubMed ID: 9146951 [TBL] [Abstract][Full Text] [Related]
39. Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford. Zehnder JL; Hiraki DD; Jones CD; Gross N; Grumet FC Thromb Haemost; 1999 Sep; 82(3):1097-9. PubMed ID: 10494770 [TBL] [Abstract][Full Text] [Related]
40. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance. van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]